Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 698-699

  Widmer, N ^a   Gotta, V ^a   Haouala, A ^a   Decosterd, L A ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Chronic myeloid leukemia; Imatinib; Nilotinib; Pharmacodynamics; Pharmacokinetics; Prognostic factors; Therapeutic drug monitoring

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANALYTIC METHOD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; EDITORIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MONITORING, PHYSIOLOGIC; OSMOLAR CONCENTRATION; PATIENT COMPLIANCE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 77952108627     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.12.009     Document Type: Editorial

References (23)

1. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
2. Sattler M., Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
3. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
4. Tanaka R., Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008, 8:1387-1398.
5. Ramirez P., DiPersio J.F. Therapy options in imatinib failures. Oncologist 2008, 13:424-434.
6. Clark R.E. Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. Leuk Res 2009, 33:1151-1155.
7. Breccia M., Alimena G. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?. Leuk Res 2009, 33:1450-1451.
8. Cortes J.E., Egorin M.J., Guilhot F., et al. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537-1544.
9. Larson R.A., Druker B.J., Guilhot F.A., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
10. Widmer N., Decosterd L.A., Csajka C., et al. Population pharmacokinetics of imatinib and role of alpha-1-acid glycoprotein. Br J Clin Pharmacol 2006, 62:97-112.
11. Gardner E.R., Burger H., van Schaik R.H., et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006, 80:192-201.
12. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
13. Singh N., Kumar L., Meena R., et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 2009, 65:545-549.
14. Widmer N., Decosterd L.A., Leyvraz S., et al. Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008, 98:1633-1640.
15. Demetri G.D., Wang Y., Wehrle E., et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009, 27:3141-3147.
16. Houk B.E., Bello C.L., Poland B., et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2009, 10.1007/s00280-009-1170-y.
17. Zandvliet A.S., Schellens J.H., Beijnen J.H., et al. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet 2008, 47:487-513.
18. Baccarani M, Guilhot F, Hehlmann R, Guidi G, One year of best practice in the management of chronic myeloid leukemia: Interim results of EUTOS for CML. Presented at: EUTOS for CML Webcast. Cannes, France, October 17, 2008.
19. De Francia S., D'Avolio A., De Martino F., et al. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1721-1726.
20. Haouala A, Zanolari B., Rochat B., et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1982-1996.
21. Demetri G.D., Casali P.G., Blay J.Y., et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:5910-5916.
22. Davies A., Hayes A.K., Knight K., et al. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res 2010, 34:702-707.
23. I-COME: Imatinib COncentration Monitoring Evaluation: the clinical usefulness of " routine" versus " rescue" therapeutic drug monitoring (TDM) interventions in chronic myeloid leukaemia (CML) patients. August 18, 2009 [cited December 8, 2009]. Available from: http://www.controlled-trials.com/ISRCTN31181395.